Oligometastatic Mesothelioma Treated with Ablative Radiotherapy (OMAR): A Multicenter Study
Davide Franceschini(IRCCS Humanitas Research Hospital), Marta Scorsetti(Humanitas University), Gaia Piperno(Unknown), Filippo Alongi(Ospedale Sacro Cuore Don Calabria), Patrizia Ciammella(Azienda Sanitaria Unità Locale di Reggio Emilia), Matthias Gückenberger(University Hospital of Zurich), Paolo Borghetti(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Rosario Mazzola(Ospedale Sacro Cuore Don Calabria), Giovanni Luca Ceresoli(Humanitas Gavazzeni), Barbara Alicja Jereczek‐Fossa(European Institute of Oncology), Nicolaus Andratschke(University Hospital of Zurich), Ruggero Spoto(IRCCS Humanitas Research Hospital), Emanuele Alì(Azienda Sanitaria Unità Locale di Reggio Emilia), Marco Krengli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Luca Nicosia(Ospedale Sacro Cuore Don Calabria), Paolo Ghirardelli(Humanitas Gavazzeni), Matteo Sepulcri(Istituto Oncologico Veneto), Mauro Loi(Azienda Ospedaliero-Universitaria Careggi), Elisabetta Parisi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Stefano Bendoni(IRCCS Humanitas Research Hospital), Antonino Romeo(University of Messina), Patricia Frrokaj(University of Zurich), Marco Marzo(IRCCS Humanitas Research Hospital)
Cited by 0
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
|Annals of Oncology|2021|577